Table 11.
Meta-analysis on the diagnostic performance of serum markers for liver fibrosis in patients with NAFLD
| Serum marker | No. of studies | No. of patients | Significant fibrosis (≥F2) |
Advanced fibrosis (≥F3) |
Cirrhosis (F4) |
|||
|---|---|---|---|---|---|---|---|---|
| AUC | Cutoff value | AUC | Cutoff value | AUC | Cutoff value | |||
| FIB-4 [200,201] | 32 | 13,764 | 0.74 | >1.3–1.9 | 0.74–0.76 | >2.67–3.25 | 0.86–0.88 | >3.50–4.12 |
| NFS [200] | 33 | 13,337 | 0.66 | <-1.455 | 0.74–0.85 | >0.676 | - | - |
| ELF [29,202] | 16 | 5,002 | 0.82 | >-0.1068 | 0.9 | >0.3576 | - | - |
NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4 index; NFS, NAFLD fibrosis score; ELF, enhanced liver fibrosis; AUC, area under the curve.